TABLE 1.
Macaque | % IVKa |
Spot-forming cells/106 PBMC by IFN-γ ELISPOT |
IFN-γ ICS |
|||||
---|---|---|---|---|---|---|---|---|
Gag | Pol | Gag | Pol | Gag | Pol | Gag | Pol | |
E20b | 3.8 | 5.7 | 8 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
E22b | 91.3 | 31.9 | 73 | 13 | 1.7 | 1.6 | 3.3 | 0.2 |
B00c | 64.8 | 22.6 | 73 | 0 | 3.3 | 0.4 | 0.4 | 0.2 |
H8c | 85.0 | 12.7 | 593 | 8 | 13.7 | 0.2 | 27.0 | 0.2 |
H20c | 92.3 | 99.8 | 230 | 20 | 3.4 | 2.1 | 5.2 | 3.0 |
H21c | 98.3 | 99.2 | 183 | 65 | 4.7 | 4.3 | 8.8 | 5.0 |
IVK experiments were performed 2 weeks after SHIVmn229 challenge. IFN-γ ELISPOT and ICS data were from 2 and 3 weeks postchallenge, respectively.
Macaques were not vaccinated with DNA and FPV but previously studied for IVK.
Macaques previously vaccinated with DNA and FPV and studied for IVK.